Drooms AG is a leading European provider of secure cloud solutions. This software specialist facilitates highly secure access to confidential documents as well as the ability to safely exchange them with third parties beyond company firewalls. Confidential business processes, such as financing and licensing projects or Board Communication are handled securely, transparently and efficiently with Drooms. Headquartered in Frankfurt, Germany´s banking hub, Drooms is also expanding its global market presence and now has offices in Munich, London, Paris, Amsterdam, Zug, Madrid, Milan and Vienna. The company is well positioned to facilitate large-scale local and multi-jurisdictional transactions. Their professional expertise, top-tier reputation and innovative processes have laid the groundwork for a growing reputation in this market space. Selected References include Astellas, Hormosan, HRA Pharma, Novartis, NovImmune SA and Siemens.
Hylomorph is a newly formed medical device company based in Switzerland with a breakthrough technology to improve the biocompatibility of medical implants. Upon implantation, devices such as cardiac implantable electronic devices or breast implants are perceived as a foreign body resulting in the formation of fibrotic (scar) tissue around the implant over time. This can lead to severe complications both for patient and surgeon during revision surgery resulting in additional costs of care.
Hylomorph has developed a novel material from biocellulose which has a unique macro and micro morphology disrupting both protein and fibroblast adhesion, blocking the process of fibrotic capsule formation. This material can be formed into a variety of shapes which can be placed around the implantable device, both acting as a physical barrier and an active anti-fibrotic membrane.
Hylomorph is applying this technology to the two largest implantable medical device markets: cardiac implantable electronic devices, and breast implants, aiming to reduce significantly the clinical and economic problems associated with fibrotic capsule formation. Clinical trials will commence in 2018 with CE mark and FDA 510k clearance planned for 2020.
At Dicronis, we are developing the first DIY lymphatic activity tracker, featuring a microneedles-covered patch and a wearable detector. The microneedles-mediated skin delivery of a fluorescent agent and the measure of its disappearance rate with a coupled wearable device allows for assessment of the dermal lymphatic function. Being minimally-invasive, painless and simple empower it to be used in a home setting by the patient, and accordingly, allow for a much better monitoring on the lymphatic health. This is highly relevant for basic or nutritional research purposes, to evaluate novel therapeutics or as diagnostic biomarker in diseases where this is disrupted, leading to debilitating consequences. For instance, lymphedema, a condition frequently occurring after cancer treatments, outlined by the swelling of a limb. Early diagnosis of the disease is highly crucial to ensure conservative measures, e.g. lymphatic draining massages or compression garments, are employed early-on for best management of the disease. Indeed, current methods of diagnosis of lymphedema are driven, by the clinical manifestation of the symptoms, which delay disease management and therefore worsen the prognosis.
Responsive Web Design powered by 